A potential innovative therapeutic using synthetic lethal strategy for the treatment of solid tumors. Insilico expects to submit the pre-IND application for this candidate with the CDE in 2024 Q4. (IMAGE)

InSilico Medicine

A potential innovative therapeutic using synthetic lethal strategy for the treatment of solid tumors. Insilico expects to submit the pre-IND application for this candidate with the CDE in 2024 Q4.

Caption

When initiating the collaboration, Fosun Pharma proposed four targets of interest, and the target of the PCC nominated in this program is one of them and plays a critical role in DNA damage repair mechanisms. 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.